MDT

96.57

-0.29%↓

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.3

Buy Sell

Overview

Share price change

24h

Current

Min

1.27

Max

1.32

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+129.01% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-21M 82M
Previous open	1.3
Previous close	1.3

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sty 2026, 19:05 UTC

Major Market Movers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 sty 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 sty 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 sty 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 sty 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 sty 2026, 23:10 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 sty 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 sty 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 sty 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 sty 2026, 21:08 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 sty 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 sty 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 sty 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 sty 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 sty 2026, 19:03 UTC

Earnings

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 sty 2026, 18:50 UTC

Earnings

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 sty 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 sty 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

13 sty 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 sty 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 sty 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 sty 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 sty 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

129.01% upside

12 Months Forecast

Average 3 USD 129.01%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.